Updates

EKF Diagnostics - Three acquisitions in a month

April 2014

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

EKF has finally added much needed critical scale with three acquisitions supported by a placing and open offer of 62.8m new shares (23% of the equity) at 35p, to raise £22m. The biggest deal is Selah, a clinical diagnostic company focused on personalised medicine, which is hot on everyoneâ€™s lips. It specialises in the detection of molecular biomarkers to diagnose and monitor disease, detect risk and identify which therapies will work best for individual patients. Selah is expected to generate c.$20m proforma revenues and an operating profit of around $4m this year and EKF has paid US$70.6m (US$35.6m in shares with US$35m deferred) - which is 3.5x sales and c18x profit. The second deal is DiaSpect, a Swedish IVD company ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Kalibrate

Optimal Payments

EKF Diagnostics (January 2015)

EKF Diagnostics (October 2014)

EKF Diagnostics (June 2014)

EKF Diagnostics (March 2014)

EKF Diagnostics (October 2013)

EKF Diagnostics (April 2013)

EKF Diagnostics (October 2012)

EKF - Forecasts upgraded again (April 2012)

EKF DIagnostics (October 2011)

EKF - Second large diagnostic deal sends EKF full square into the US market (July 2011)

EKF Diagnostics (December 2010)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X